Tandem Diabetes Care Inc TNDM
We take great care to ensure that the data presented and summarized in this overview for TANDEM DIABETES CARE INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TNDM
View all-
Black Rock Inc. New York, NY11.1MShares$225 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.29MShares$148 Million0.0% of portfolio
-
Sessa Capital Im, L.P. New York, NY4.47MShares$90.4 Million3.55% of portfolio
-
Gw&K Investment Management, LLC Boston, MA2.86MShares$57.9 Million0.51% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO2.72MShares$55 Million0.95% of portfolio
-
State Street Corp Boston, MA2.69MShares$54.4 Million0.0% of portfolio
-
Hood River Capital Management LLC Palm Beach Gardens, FL2.31MShares$46.8 Million0.84% of portfolio
-
Stephens Investment Management Group LLC1.71MShares$34.5 Million0.5% of portfolio
-
Paradice Investment Management LLC1.65MShares$33.4 Million7.25% of portfolio
-
Geode Capital Management, LLC Boston, MA1.56MShares$31.5 Million0.0% of portfolio
Latest Institutional Activity in TNDM
Top Purchases
Top Sells
About TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Insider Transactions at TNDM
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 02
2025
|
Dick Allen Director |
SELL
Bona fide gift
|
Indirect |
1,000
-100.0%
|
$19,000
$19.88 P/Share
|
May 29
2025
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
BUY
Other acquisition or disposition
|
Indirect |
11,200
+32.8%
|
-
|
May 29
2025
|
Elizabeth Anne Gasser EVP, Chief Strategy Officer |
SELL
Other acquisition or disposition
|
Direct |
11,200
-100.0%
|
-
|
May 22
2025
|
Dick Allen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+18.45%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Joao Paulo Falcao Malagueira Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+26.85%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Christopher J Twomey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+21.87%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Peyton R Howell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+17.23%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Rebecca B Robertson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+24.14%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Myoungil Cha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+26.85%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Kathleen Mc Groddy Goetz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+19.73%
|
$87,740
$20.64 P/Share
|
May 22
2025
|
Rajwant Sodhi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,387
+22.04%
|
$87,740
$20.64 P/Share
|
May 15
2025
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,907
-2.13%
|
$63,954
$22.7 P/Share
|
May 15
2025
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,121
+5.28%
|
-
|
May 15
2025
|
Leigh Vosseller EVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,359
+4.54%
|
$20,385
$15.64 P/Share
|
May 15
2025
|
Jean Claude Kyrillos EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
171
+1.57%
|
$3,249
$19.3 P/Share
|
May 15
2025
|
John F Sheridan PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,470
-4.06%
|
$362,340
$22.7 P/Share
|
May 15
2025
|
John F Sheridan PRESIDENT & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,429
+6.89%
|
$162,145
$5.68 P/Share
|
May 15
2025
|
John F Sheridan PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,359
+1.66%
|
$20,385
$15.64 P/Share
|
May 15
2025
|
Rick Carpenter Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,014
-3.21%
|
$44,308
$22.7 P/Share
|
May 15
2025
|
Rick Carpenter Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,622
+8.01%
|
-
|
Last 12 Months Summary
Exercise of conversion of derivative security | 253K shares |
---|---|
Grant, award, or other acquisition | 9.41K shares |
Other acquisition or disposition | 11.2K shares |
Open market or private purchase | 11.1K shares |
Payment of exercise price or tax liability | 88.8K shares |
---|---|
Other acquisition or disposition | 11.2K shares |
Bona fide gift | 7.64K shares |
Open market or private sale | 40K shares |